ArticleJournal of immunological methods2015
Poor correlation between T-cell activation assays and HLA-DR binding prediction algorithms in an immunogenic fragment of Pseudomonas exotoxin A.
Article in Journal of immunological methods, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 26 citations in OpenAlex.
- T-Cell Dependent Immunogenicity of Protein Therapeutics Pre-clinical Assessment and Mitigation-Updated Consensus and Review 2020.Frontiers in immunology · 2020Pooled it
- Article
- Integrated computational and experimental immunoengineering of adeno-associated virus capsid T cell epitopes in mice.Nature communications · 2026Article
- Assessing MAPPs assay as a tool to predict the immunogenicity potential of protein therapeutics.Life science alliance · 2024Article
- Identification of Immunogenic MHC Class II Human HER3 Peptides that Mediate Anti-HER3 CD4Cancer immunology research · 2022Article
- Immune Complex Formation Is Associated With Loss of Tolerance and an Antibody Response to Both Drug and Target.Frontiers in immunology · 2021Article
- Immunogenicity of Immunotoxins ContainingFrontiers in immunology · 2020Review
- Strategies to Reduce the Immunogenicity of Recombinant Immunotoxins.The American journal of pathology · 2018Review
- An automated benchmarking platform for MHC class II binding prediction methods.Bioinformatics (Oxford, England) · 2018Article
- Detection of Memory B Activity Against a Therapeutic Protein in Treatment-Naïve Subjects.The AAPS journal · 2018Article
- Addressing the Immunogenicity of the Cargo and of the Targeting Antibodies with a Focus on Demmunized Bacterial Toxins and on Antibody-Targeted Human Effector Proteins.Biomedicines · 2017Review
- A Proposal to Redefine Clinical Immunogenicity Assessment.The AAPS journal · 2017Article
- Elimination of murine and human T-cell epitopes in recombinant immunotoxin eliminates neutralizing and anti-drug antibodies in vivo.Cellular & molecular immunology · 2017Article
- Rational design of low immunogenic anti CD25 recombinant immunotoxin for T cell malignancies by elimination of T cell epitopes in PE38.Cellular immunology · 2017Article
- Role of HLA-DP in the Presentation of Epitopes from the Truncated Bacterial PE38 Immunotoxin.The AAPS journal · 2017Article
- Improving the efficacy and safety of biologic drugs with tolerogenic nanoparticles.Nature nanotechnology · 2016Article
- Current tools for predicting cancer-specific T cell immunity.Oncoimmunology · 2016Review
- CD4+ T-cell epitope prediction using antigen processing constraints.Journal of immunological methods · 2016Article
- Immunogenicity of therapeutic recombinant immunotoxins.Immunological reviews · 2016Review
- Augmented Binary Substitution: Single-pass CDR germ-lining and stabilization of therapeutic antibodies.Proceedings of the National Academy of Sciences of the United States of America · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
The ability to identify immunogenic determinants that activate T-cells is important for the development of new vaccines, allergy therapy and protein therapeutics. In silico MHC-II binding prediction algorithms are often used for T-cell epitope identification. To understand how well those programs predict immunogenicity, we computed HLA binding to peptides spanning the sequence of PE38, a fragment of an anti-cancer immunotoxin, and compared the predicted and experimentally identified T-cell epitopes. We found that the prediction for individual donors did not correlate well with the experimental data. Furthermore, prediction of T-cell epitopes in an HLA heterogenic population revealed that the two strongest epitopes were predicted at multiple cutoffs but the third epitope was predicted negative at all cutoffs and overall 4/9 epitopes were missed at several cutoffs. We conclude that MHC class-II binding predictions are not sufficient to predict the T-cell epitopes in PE38 and should be supplemented by experimental work.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.